The Antiandrogen Withdrawal Syndrome

Overview

Journal Urol Res

Specialty Urology

Date 1997 Jan 1

PMID 9144890

Citations 4

Authors

M P Wirth

S E Froschermaier

Affiliations

Soon will be listed here.

Abstract

In 1989 the unanticipated agonist effect of antiandrogens on LNCaP prostate cancer cells was detected. A "flutamide withdrawal syndrome" was first described by Kelly and Scher [15], who reported a decrease in serum prostate-specific antigen (PSA) levels after the removal of flutamide from the treatment regimen. In the last few years the paradoxical response to antiandrogens has also been reported for bicalutamide, chlormadinone acetate and others. Therefore the name of the syndrome has changed to "antiandrogen withdrawal syndrome." Several reasons such as mutations in the androgen receptor or a direct stimulatory effect of the antiandrogen for this effect have been discussed, but the exact molecular mechanism remains unclear. However, in patients with hormonally relapsed prostate cancer, a trial of "withdrawal therapy" is required prior to the initiation of toxic therapies.

Citing Articles

High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.

Xie J, Molck C, Paquet-Fifield S, Butler L, Sloan E, Ventura S Oncotarget. 2016; 7(28):44492-44504.

PMID: 27283984 PMC: 5190113. DOI: 10.18632/oncotarget.9876.

Hormones and the neuromuscular control of courtship in the golden-collared manakin (Manacus vitellinus).

Schlinger B, Barske J, Day L, Fusani L, Fuxjager M Front Neuroendocrinol. 2013; 34(3):143-56.

PMID: 23624091 PMC: 3995001. DOI: 10.1016/j.yfrne.2013.04.001.

Isolation and characterization of the androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide.

Wang C, Young W, Chang C Endocrine. 2000; 12(1):69-76.

PMID: 10855693 DOI: 10.1385/ENDO:12:1:69.

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.

Miyamoto H, Yeh S, Wilding G, Chang C Proc Natl Acad Sci U S A. 1998; 95(13):7379-84.

PMID: 9636157 PMC: 22623. DOI: 10.1073/pnas.95.13.7379.

References

Newmark J, Hardy D, Tonb D, Carter B, Epstein J, Isaacs W . Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A. 1992; 89(14):6319-23. PMC: 49492. DOI: 10.1073/pnas.89.14.6319. View

Sasagawa I, Satomi S . Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer. Br J Urol. 1990; 65(3):278-81. DOI: 10.1111/j.1464-410x.1990.tb14727.x. View

Boring C, Squires T, Tong T . Cancer statistics, 1992. CA Cancer J Clin. 1992; 42(1):19-38. DOI: 10.3322/canjclin.42.1.19. View

Veldscholte J, Ris-Stalpers C, Kuiper G, Jenster G, Berrevoets C, Claassen E . A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990; 173(2):534-40. DOI: 10.1016/s0006-291x(05)80067-1. View

Belani C, Pearl P, WHITLEY N, Aisner J . Tamoxifen withdrawal response. Report of a case. Arch Intern Med. 1989; 149(2):449-50. View

Wilding G, Chen M, Gelmann E . Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate. 1989; 14(2):103-15. DOI: 10.1002/pros.2990140204. View

Bruchovsky N, Goldenberg S, Rennie P, Gleave M . [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma]. Urologe A. 1995; 34(5):389-92. View

Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A . Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst. 1994; 86(3):222-7. DOI: 10.1093/jnci/86.3.222. View

Small E, Carroll P . Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 1994; 43(3):408-10. DOI: 10.1016/0090-4295(94)90092-2. View

10.

Cusan L, Gomez J, Dupont A, Diamond P, Lemay M, Moore S . Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide. Prostate. 1994; 24(5):257-61. DOI: 10.1002/pros.2990240507. View

11.

Nieh P . Withdrawal phenomenon with the antiandrogen casodex. J Urol. 1995; 153(3 Pt 2):1070-2; discussion 1072-3. View

12.

Figg W, Sartor O, Cooper M, Thibault A, Bergan R, Dawson N . Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med. 1995; 98(4):412-4. DOI: 10.1016/S0002-9343(99)80323-4. View

13.

Akakura K, Akimoto S, Ohki T, Shimazaki J . Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology. 1995; 45(4):700-4; discussion 704-5. DOI: 10.1016/S0090-4295(99)80070-3. View

14.

Dawson N, McLeod D . Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol. 1995; 153(6):1946-7. View

15.

Moul J, Srivastava S, McLeod D . Molecular implications of the antiandrogen withdrawal syndrome. Semin Urol. 1995; 13(2):157-63. View

16.

Kelly W, Scher H . Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993; 149(3):607-9. DOI: 10.1016/s0022-5347(17)36163-3. View

17.

Scher H, Kelly W . Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993; 11(8):1566-72. DOI: 10.1200/JCO.1993.11.8.1566. View

18.

Dupont A, Gomez J, Cusan L, Koutsilieris M, Labrie F . Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol. 1993; 150(3):908-13. DOI: 10.1016/s0022-5347(17)35646-x. View

19.

Taplin M, Bubley G, Shuster T, FRANTZ M, Spooner A, Ogata G . Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995; 332(21):1393-8. DOI: 10.1056/NEJM199505253322101. View

20.

Bissada N, Kaczmarek A . Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol. 1995; 153(6):1944-5. View